Genocea Biosciences, Inc. (GNCA) Earns Overweight Rating from Piper Jaffray Companies

Piper Jaffray Companies restated their overweight rating on shares of Genocea Biosciences, Inc. (NASDAQ:GNCA) in a research note published on Thursday, November 2nd, The Fly reports. They currently have a $5.00 price objective on the biotechnology company’s stock.

A number of other research firms also recently commented on GNCA. Zacks Investment Research downgraded shares of Genocea Biosciences from a buy rating to a hold rating in a research report on Monday, July 17th. Needham & Company LLC raised shares of Genocea Biosciences from a hold rating to a buy rating and set a $12.00 target price on the stock in a research report on Monday, July 24th. ValuEngine raised shares of Genocea Biosciences from a sell rating to a hold rating in a research report on Monday, July 24th. Cowen and Company restated an outperform rating and issued a $40.00 price target on shares of Genocea Biosciences in a report on Tuesday, July 25th. Finally, Stifel Nicolaus cut shares of Genocea Biosciences from a buy rating to a hold rating and lowered their target price for the stock from $15.00 to $2.50 in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $6.06.

Shares of Genocea Biosciences (GNCA) opened at $1.16 on Thursday. The company has a debt-to-equity ratio of 2.51, a current ratio of 1.55 and a quick ratio of 1.55. Genocea Biosciences has a twelve month low of $1.03 and a twelve month high of $7.29.

Genocea Biosciences (NASDAQ:GNCA) last issued its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.08). During the same period in the previous year, the company posted ($0.45) EPS. equities analysts expect that Genocea Biosciences will post -1.91 earnings per share for the current fiscal year.

WARNING: This news story was published by BBNS and is the sole property of of BBNS. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://baseballnewssource.com/markets/piper-jaffray-companies-reaffirms-overweight-rating-for-genocea-biosciences-inc-gnca/1752989.html.

Institutional investors and hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP acquired a new position in shares of Genocea Biosciences during the 2nd quarter valued at about $100,000. Ameriprise Financial Inc. boosted its position in shares of Genocea Biosciences by 11.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 22,233 shares of the biotechnology company’s stock valued at $119,000 after acquiring an additional 2,300 shares during the last quarter. State of Wisconsin Investment Board acquired a new position in Genocea Biosciences in the second quarter valued at about $125,000. Rhumbline Advisers acquired a new position in Genocea Biosciences in the second quarter valued at about $157,000. Finally, New York State Common Retirement Fund acquired a new position in Genocea Biosciences in the second quarter valued at about $159,000. 34.05% of the stock is currently owned by institutional investors.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses.

The Fly

Analyst Recommendations for Genocea Biosciences (NASDAQ:GNCA)

Receive News & Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Toronto Blue Jays Launch Internal Investigation on PED Use
Toronto Blue Jays Launch Internal Investigation on PED Use
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player


Leave a Reply

 
© 2006-2017 BBNS.